You are here: Industry Insights > ImmVira

News List

ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data prnasia
January 19, 2022
ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study...
ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial prnasia
August 11, 2021
ImmVira announced that it has initiated its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011). The first patient has been dosed, receiving MVR-T3011 intravenous (IV) administration in the U.S. on August 10, 2021.
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial prnasia
August 10, 2021
ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval from National Medical Products Administration for clinical trial for treatments using intravenous administration ...
ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials prnasia
July 19, 2021
On July 18, 2021, ImmVira inaugurated a pilot-scale production line in Shenzhen and officially initiated its in-house production of our next-generation oncolytic viruses (OV) used for IND applications and Phase I/II clinical trials.
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China prnasia
June 15, 2021
ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in both China and the U.S. on May 28 2021 and June 11 2021 ...
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021 prnasia
June 03, 2021
ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021 for the first time.
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration prnasia
April 20, 2021
On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting.
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting prnasia
April 09, 2021
ImmVira announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8 2021.
ImmVira Announces Series C Financing with Leading Specialist Investors prnasia
January 04, 2021
ImmVira Group Company, a biotechnology platform dedicated to the development of oncolytic virus and vector type approaches to create more effective and safer therapies against cancer, announced the signing of Series C financing.
ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital prnasia
September 27, 2020
ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing of US$10 million Series B Plus strategic financing.